Abstract
BAX gene mutations occur in approximately 50% of RER+ colorectal cancers. To determine the role of these mutations in tumour progression we analysed multiple different tumour sites from RER+ colorectal cancers for BAX mutations. Sixty colorectal carcinomas were analysed for microsatellite instability at loci BAT-26, L-myc, TGFβRII, D13S160 and D2S123. Twelve out of 60 tumours (20%) were RER+. Forty-five different tumour sites from the 12 RER+ carcinomas were analysed for BAX mutations at the [(G)8] tract in exon 3. Six out of 12 (50%) RER+ tumours showed BAX mutations, four of which showed a homogenous pattern of such mutations detected in all tumour sites. In the other two cases, BAX mutations were present in some but not all tumour sites sampled from the same patient. In contrast, TGFβRII mutations were found in 9/12 cases (75%) and in each of these were present in all the sampled sites. Two cases showed neither BAX nor TGFβRII mutation. These data suggest that mutations in TGFβRII may occur at a very early stage in tumour progression, perhaps in the founder clone. BAX mutations, however, are clearly not necessary for formation of the founder clone and can occur for the first time later in tumour progression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H, Powell SM, Jen J, Hamilton SR, Petersen GM, Kinzler KW, Vogelstein B and Delachapelle A. . 1993 Science 260: 812–816.
Brown R. . 1997 Br. Med. Bull. 53: 466–477.
Bubb VJ, Curtis LJ, Cunningham C, Dunlop MG, Carothers AD, Morris RG, White S, Bird CC and Wyllie AH. . 1996 Oncogene 12: 2641–2649.
Chung YJ, Park SW, Song JM, Lee KY, Seo EJ, Choi SW and Rhyu MG. . 1997 Oncogene 15: 1719–1726.
Goelz SE, Hamilton SR and Vogelstein B. . 1985 Biochem. Biophys. Res. Commun. 130: 118–126.
Hoang JM, Cottu PH, Thuille B, Salmon RJ, Thomas G and Hamelin R. . 1997 Cancer Res. 57: 300–303.
Huang J, Papadopoulos N, Mckinley AJ, Farrington SM, Curtis LJ, Wyllie AH, Zheng S, Willson JKV, Markowitz SD, Morin P, Kinzler KW, Vogelstein B and Dunlop MG. . 1996 Proc. Natl. Acad. Sci. USA 93: 9049–9054.
Jacoby RF, Marshall DJ, Kailas S, Schlack S, Harms B and Love R. . 1995 Gastroenterology 109: 73–82.
Kroemer G. . 1997 Nature Med. 3: 614–620.
Markowitz S, Wang J, Myeroff L, Parsons R, Sun LZ, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M and Willson JKV. . 1995 Science 268: 1336–1338.
Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC. . 1994 Oncogene 9: 1799–1805.
Miyashita T and Reed JC. . 1995 Cell 80: 293–299.
Oltvai ZN, Milliman CL and Korsmeyer SJ. . 1993 Cell 74: 609–619.
Ouyang H, Furukawa T, Abe T, Kato Y and Horii A. . 1998 Clin. Cancer Res. 4: 1071–1074.
Parsons R, Myeroff LL, Liu B, Willson JKV, Markowitz SD, Kinzler KW and Vogelstein B. . 1995 Cancer Res. 55: 5548–5550.
Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC and Perucho M. . 1997 Science 275: 967–969.
Samowitz WS and Slattery ML. . 1997 Am. J. Pathol. 151: 33–35.
Thibodeau SN, Donovan KA, Tester DJ, Bren GD, Halling KC, Cunningham J, Morris AV and Roche PC. . 1993 Am. J. Hum. Genet. (Suppl.) 53: 1.
White E. . 1996 Genes Dev. 10: 1–15.
Wrana JL, Attisano L, Wieser R, Ventura F and Massague J. . 1994 Nature 370: 341–347.
Yagi OK, Akiyama Y, Nomizu T, Iwama T, Endo M and Yuasa Y. . 1998 Gastroenterology 114: 268–274.
Yamamoto H, Sawai H, Weber TK, RodriguezBigas MA and Perucho M. . 1998 Cancer Res. 58: 997–1003.
Young J, Searle J, Buttenshaw R, Thomas L, Ward M, Chenevixtrench G and Leggett B. . 1995 Genes Chrom. Cancer 12: 251–254.
Zhou XP, Hoang JM, Li YJ, Seruca R, Carneiro F, SobrinhoSimoes M, Lothe RA, Gleeson CM, Russell SEH, Muzeau F, Flejou JF, HoangXuan K, Lidereau R, Thomas G and Hamelin R. . 1998 Genes Chrom. Cancer 21: 101–107.
Acknowledgements
The authors' work was supported by grants from Cancer Research Campaign, Association for International Cancer Research, Scottish Hospitals Endowment Research Trust, and Egyptian Education Bureau-London.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Abdel-Rahman, W., Georgiades, I., Curtis, L. et al. Role of BAX mutations in mismatch repair-deficient colorectal carcinogenesis. Oncogene 18, 2139–2142 (1999). https://doi.org/10.1038/sj.onc.1202589
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202589
Keywords
This article is cited by
-
Environmental Exposure and Tumor Heterogeneity in Colorectal Cancer Risk and Outcomes
Current Colorectal Cancer Reports (2014)
-
GAPDH, a novel regulator of the pro-apoptotic mitochondrial membrane permeabilization
Oncogene (2007)
-
Microsatellite instability and mutation analysis of candidate genes in urothelial cell carcinomas of upper urinary tract
Oncogene (2006)
-
BAX and caspase-5 frameshift mutations and spontaneous apoptosis in colorectal cancer with microsatellite instability
International Journal of Colorectal Disease (2004)
-
Mutation frequency in coding and non-coding repeat sequences in mismatch repair deficient cells derived from normal human tissue
Oncogene (2001)